Goldman Sachs
ALT icon

Goldman Sachs’s Altimmune ALT Stock Holding History

Goldman Sachs’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-286
Closed -$136K – 6548
2013
Q2 		$136K Buy
+286
New +$142K ﹤0.01% 5769

Other funds holding ALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs's ALT Position: Q2 2026 in Review

Goldman Sachs increased its Altimmune (ALT) stake by 64% in Q2 2026, buying an estimated $2.58M and bringing the position to 2,214,450 shares worth $6.73M. The position accounts for ﹤0.01% of the portfolio, ranked #3616.

Goldman Sachs first reported a position in ALT in Q2 2013 and has held it in 35 quarters since. The position peaked at $12.6M in Q4 2022. 211 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • Goldman Sachs held 2,214,450 shares of Altimmune worth $6.73M as of Q2 2026.
  • Goldman Sachs bought 863,801 Altimmune shares in Q2 2026, an estimated $2.58M.
  • Altimmune made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3616 holding.
  • Goldman Sachs first reported a position in Altimmune in Q2 2013 and has held it in 35 quarters since.
  • Goldman Sachs's Altimmune position peaked at $12.6M in Q4 2022.
  • 211 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.